Avant Diagnostics Inc. AVDX Archives

WednesdayDec 23, 2015 9:40 am

Avant Diagnostics, Inc. (AVDX) Leading the Next Advance in the ‘War on Cancer’ through the Development of OvaDx®

The American Cancer Society estimates that about 21,290 new cases of ovarian cancer will be diagnosed in 2015, and roughly 14,180 women will die from the illness within the United States. These figures outline the severity of ovarian cancer, which is currently the eighth most common cancer among women, as well as the fifth leading cause of cancer-related death among women, according to data from SEER. Over the past forty years, mortality rates for ovarian cancer have recorded a mild decline as a result of the ongoing ‘War on Cancer’, but these improvements pale in comparison to the progress made…

WednesdayDec 16, 2015 1:58 pm

Avant Diagnostics, Inc. (AVDX) Noninvasive, Pre-Symptomatic Ovarian Cancer Diagnostic Platform Could Also Address Many Other Diseases

According to the latest data from the American Cancer Society, in the U.S. alone over 21,000 women will be diagnosed with ovarian cancer this year, and more than 14,000 will perish from the disease. In most cases, ovarian cancer is detected by a combination of symptomatic expression and/or the discovery of a mass or lump during a routine pelvic examination. The disease is generally feared as a silent killer due to routinely being detected in later stages, after the problem has already become unwieldy. This is most unfortunate given that if ovarian cancer can be detected early enough, the primary…

TuesdayDec 15, 2015 11:13 am

Avant Diagnostics, Inc. (AVDX) Targets Corporate Transparency with Launch of New Website

Avant Diagnostics, Inc. (OTC: AVDX) is on a mission to maximize its levels of corporate transparency for the benefit of its customers and investors. Late last week, the company took a significant step toward realizing this goal when it unveiled its new website. The new site utilizes a number of design features aimed at making browsing both streamlined and informative for Avant’s current and potential customers and investors. The site’s investor relations section, in particular, received a considerable upgrade, incorporating helpful features such as immediate posting of press releases and automated posting of SEC filings, XBRL data, Insider Section 16…

WednesdayDec 09, 2015 2:13 pm

Avant Diagnostics, Inc. (AVDX) Aims to Provide Early Detection Solutions for Better Treatment Options

Avant Diagnostics, Inc. is a company that focuses on the commercialization of proprietary microarray-based tests for the early detection of cancers, neurodegenerative diseases, and more. The company’s leading product is OvaDx®, a non-invasive pre-screening test that detects ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. This is the market’s first large panel screening test designed to detect ovarian cancer early. With early detection, more treatment options become available for patients that should delay or prevent disease progression. OvaDx® would be an optional supplement to existing tests…

WednesdayDec 02, 2015 10:58 am

Avant Diagnostics (AVDX) Out Front in Early Detection and Screening for Ovarian Cancer

Avant Diagnostics (OTC: AVDX) is a leading medical technology company focused on advancing innovative solutions that improve upon the ways we screen for ovarian cancer. AVDX’s energy and resources aim to bring to market innovative diagnostic tests based upon the completion of the human genome sequencing project. The company works at developing a sophisticated screening test for diagnosing ovarian cancer using OvaDx® – a unique large-panel biomarker screening test for this deadly disease. OvaDx is an advanced diagnostic test used specifically for measuring the activation of the immune system in response to ovarian tumor cell development. Patient sera are used…

TuesdayNov 24, 2015 10:24 am

Avant Diagnostics (AVDX): An Ounce of Prevention is Worth a Pound of Cure

Early detection of cancer is the key to using the medicines available today to battle cancer and give the patient the best chance of beating this horrible disease and getting back to a normal life. Avant Diagnostics (AVDX) has undertaken this heroic challenge with its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test. OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Each year, cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR). Cancer costs…

WednesdayNov 18, 2015 10:04 am

Avant Diagnostics, Inc. (AVDX) Employs Impressive Leadership to Obtain Goals in Disease Prevention

Avant Diagnostics, a medical technology company, continues its objective of mapping out the entire DNA sequence of a human genome. This development would benefit the entire human population as scientists would be able to treat, prevent, and cure disease. Genome is the genetic material of an organism that consists of DNA and therefore acts as a textbook of how the human body works. Scientists would be able to identify a person’s propensity of disease through testing which would promote early treatment and hopefully a cure. Leading this innovative company as its president and CEO stands Gregg Lynn. After receiving his…

WednesdayNov 11, 2015 4:01 pm

Avant Diagnostics (AVDX) Leading an Evolution in Early Detection of Ovarian Cancer

Avant Diagnostics is a medical technology company at the forefront of driving an evolution in the screening of ovarian cancer. Its focus is centered on bringing to market innovative diagnostic tests based upon the completion of the human genome sequencing project. The company endeavors in developing a refined screening test for diagnosing ovarian cancer by way of OvaDx - the market’s first large-panel biomarker screening test for this deadly disease. OvaDx® is considered to be an advanced diagnostic test that measures the activation of the immune system in response to ovarian tumor cell development. Patient sera are applied to OvaDx®…

FridayNov 06, 2015 11:30 am

Avant Diagnostics, Inc. (AVDX) Offers A New Approach To Diagnosing A Deadly Cancer

Avant Diagnostics, a medical technology company focused on bringing to market cutting-edge diagnostic tests based upon the completion of the human genome sequencing project, has developed a sophisticated and much-needed screening test for diagnosing ovarian cancer. OvaDx is the market’s first large-panel biomarker screening test for ovarian cancer. Discoveries in genetic research offer far-reaching opportunities for impacting both the diagnosis and treatment of serious disease. It centers on identifying variations in specific genes in the genome, variations that define individual characteristics, including disease states or a statistical propensity for disease. Diagnostic tests that detect diseases early in their progression will…

ThursdayOct 29, 2015 8:43 am

Avant Diagnostics, Inc. (AVDX) Blazing Trail to Fulfill Need for Effective Ovarian Cancer Screening Technology

Each year, approximately 20,000 women in the United States get ovarian cancer, which causes more deaths than any other gynecologic cancer, according to the Centers for Disease Control. While the disease often causes signs and symptoms, the signs can be hard to recognize; and for the time being, the market is lacking an available, effective screening test for ovarian cancer. Thanks to one particular advancing technology, however, this could soon change. Because ovarian cancer symptoms can be hard to recognize, effective screening is vital, and medical diagnostic technology company Avant Diagnostics stands at the edge of breakthrough. The company is…

Site Search

Company Search

Tag: Avant Diagnostics Inc. AVDX